Rua Bioscience announces launch of new products in the UK

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com






FOR PUBLIC RELEASE


NZX Limited
Wellington

19 December 2024


Rua Bioscience announces launch of new products in the UK

Rua Bioscience is proud to announce the launch of three medicinal cannabis products in
the United Kingdom. This marks a significant milestone in Rua's international growth
strategy, with the UK positioned as a key market alongside Germany, Australia, and New
Zealand. These new products will be distributed exclusively by Target Healthcare, a
leading distributor of unlicenced medicines in the UK.

Unlocking the Potential of a Growing Market

The UK medicinal cannabis market is estimated to be one of the fastest growing in
Europe, driven by an increasing number of patients seeking alternative medicines for the
treatment of chronic pain, anxiety, and other conditions. The market is approximately
$60m and growing at over 100% per annum in the last two years. With a population of
68 million, Rua expects this market to grow significantly in the next two years. Rua's
entry into this market is the next stage in the establishment of a consistent supply line
and respected presence.

"Expanding into the UK is an exciting step for Rua," said Paul Naske, CEO. "This launch is
a direct execution of our strategy. We are focused on establishing strong supply lines
into high value markets which in turn provide a route to market for our unique NZ
cannabis varieties. Partnering with Target Healthcare ensures we can reach UK patients
efficiently and effectively in this key market."

A Strong Partnership

Target Healthcare's extensive experience in the UK market and its expert knowledge of
unlicensed medicines make them an ideal partner for Rua Bioscience. Together, the two
companies aim to bring additional products to the market in the coming years that
prioritise patient needs.

MARKET UPDATE

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
Looking Ahead

With this launch, Rua Bioscience continues to establish itself as a leader in the medicinal
cannabis industry with diversified revenue streams in four key markets. With UK
distribution now established alongside channels in Germany, Australia and New Zealand
Rua will focus on revenue growth and product line expansion.


ENDS  
 

The person who authorised this announcement:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154